Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varicella zoster virus vaccine - Sinovac (Dalian) Vaccine Technology

Next Previous
Drug Profile

Varicella zoster virus vaccine - Sinovac (Dalian) Vaccine Technology

Alternative Names: Live attenuated varicella vaccine - Sinovac Biotech/Dalian Vaccine Technology; PROVARIX; Varicella vaccine, live - Sinovac (Dalian) Vaccine Technology; Varicella zoster vaccine - Sinovac Biotech/Dalian Vaccine Technology

Latest Information Update: 23 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; Sinovac (Dalian) Vaccine Technology; Sinovac Biotech
  • Developer Sinovac (Dalian) Vaccine Technology; Sinovac Biotech
  • Class Attenuated vaccines; Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Varicella zoster virus infections

Most Recent Events

  • 16 Mar 2026 Sinovac (Dalian) Vaccine Technology plans a phase III trial for Varicella zoster virus infections (In children, In infants, Prevention) in Vietnam in May 2026 (NCT07473427)
  • 28 Jan 2026 Phase-III clinical trials in Varicella zoster virus infections (In children, In infants, Prevention) in Turkey (Parenteral) (NCT07475000)
  • 06 Jan 2026 Phase-I/II clinical trials in Varicella zoster virus infections (In the elderly, Prevention, In adults) in China (IM) (NCT07400003)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top